Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus

下一代表型抗菌药物敏感性测试平台：快速结果和全面的菜单

基本信息

批准号：
10477291
负责人：
ERIC STERN
金额：
$ 98.2万
依托单位：
SELUX DIAGNOSTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-01-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10477291
关键词：
Address Adopted Adoption American Antibiotic Resistance Antibiotic susceptibility Antibiotics Antimicrobial Resistance Antimicrobial susceptibility Benchmarking Biological Assay Blood Clinical Clinical Medicine Communicable Diseases Computer software Data Epidemic Evaluation Feedback Freezing Funding Future Goals Gold Health Healthcare Infection Laboratories Lead Letters Longevity Manuals Methods Molds Multi-Drug Resistance Oral Patient Care Patients Performance Pharmaceutical Preparations Phase Phenotype Positioning Attribute Price Process Readiness Reagent Reference Standards Reflex action Sampling Site Small Business Innovation Research Grant Sonication System Test Result Testing Time Universities Work accurate diagnosis antimicrobial base combat cost cost effectiveness design disease diagnostic improved individual patient next generation novel performance tests rapid diagnosis recruit usability

项目摘要

The goal of this CRP SBIR proposal is to fund four projects to advance the commercial readiness of Selux’s rapid, comprehensive, low-cost, phenotypic antibiotic susceptibility test (AST) system. Selux’s next-generation phenotyping (NGP) platform uniquely enables rapid AST with comprehensive antimicrobial menus of >50 drugs at a low cost from isolates and positive blood culture samples. Aims 1 and 2 focus on cost reduction projects important for early customer adoption. Aim 1 comprises analytical studies to support multiplex oral panels and Aim 2 is a DFM redesign of the Analyzer consumable pack. Aims 3 and 4 focuses on work necessary for later customer adoption. Aim 3 is a yearlong benchmarking study that will compare Selux NGP performance against legacy AST systems and reference methods. By improving system workflows and benchmarking AST performance across legacy systems CRP funding will help position Selux NGP as the dominant AST platform of the future.

CRP SBIR 提案的目标是资助四个项目以推进商业化 Selux 的快速、全面、低成本、表型抗生素敏感性准备就绪 Selux 的下一代表型分析 (NGP) 平台独特地实现了快速分析。 AST 具有超过 50 种药物的全面抗菌菜单，成本低廉，来自分离株和目标 1 和 2 重点关注对早期重要的成本降低项目。目标 1 包括支持多重口头小组和目标的分析研究。 2 是分析仪耗材包的 DFM 重新设计，目标 3 和 4 重点工作。目标 3 是一项为期一年的基准研究，对于以后的客户采用是必要的。将 Selux NGP 性能与传统 AST 系统和参考方法进行比较。改进系统工作流程并在旧系统 CRP 上对 AST 性能进行基准测试资金将有助于将 Selux NGP 定位为未来占主导地位的 AST 平台。